101 related articles for article (PubMed ID: 23722284)
1. Polymorphism and overexpression of HER2/neu among ovarian carcinoma women from Tiruchirapalli, Tamil Nadu, India.
Shanmughapriya S; Senthilkumar G; Arun S; Vinodhini K; Sudhakar S; Natarajaseenivasan K
Arch Gynecol Obstet; 2013 Dec; 288(6):1385-90. PubMed ID: 23722284
[TBL] [Abstract][Full Text] [Related]
2. Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk.
Xie D; Shu XO; Deng Z; Wen WQ; Creek KE; Dai Q; Gao YT; Jin F; Zheng W
J Natl Cancer Inst; 2000 Mar; 92(5):412-7. PubMed ID: 10699071
[TBL] [Abstract][Full Text] [Related]
3. CYP1A1 gene polymorphism and risk of epithelial ovarian neoplasm.
Aktas D; Guney I; Alikasifoglu M; Yüce K; Tuncbilek E; Ayhan A
Gynecol Oncol; 2002 Aug; 86(2):124-8. PubMed ID: 12144816
[TBL] [Abstract][Full Text] [Related]
4. Association of HER2 codon 655 polymorphism with ovarian cancer.
Watrowski R; Castillo-Tong DC; Schuster E; Fischer MB; Speiser P; Zeillinger R
Tumour Biol; 2016 Jun; 37(6):7239-44. PubMed ID: 26666819
[TBL] [Abstract][Full Text] [Related]
5. HER-2/neu gene codon 655 (Ile/Val) polymorphism in breast carcinoma patients.
Sezgin E; Sahin FI; Yagmurdur MC; Demirhan B
Genet Test Mol Biomarkers; 2011 Mar; 15(3):143-6. PubMed ID: 21204706
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases.
Naidu R; Yip CH; Taib NA
Neoplasma; 2008; 55(2):87-95. PubMed ID: 18237245
[TBL] [Abstract][Full Text] [Related]
7. HER-2 [Ile655Val] polymorphism in association with breast cancer risk: a population-based case-control study in Slovakia.
Zúbor P; Vojvodová A; Danko J; Kajo K; Szunyogh N; Lasabová Z; Biringer K; Visnovský J; Dókus K; Galajda P; Plank L
Neoplasma; 2006; 53(1):49-55. PubMed ID: 16416013
[TBL] [Abstract][Full Text] [Related]
8. HER2 codon 655 polymorphism is associated with advanced uterine cervical carcinoma.
Kruszyna Ł; Lianeri M; Roszak A; Jagodziński PP
Clin Biochem; 2010 Apr; 43(6):545-8. PubMed ID: 20026098
[TBL] [Abstract][Full Text] [Related]
9. A single nucleotide polymorphism in the transmembrane domain coding region of HER-2 is associated with development and malignant phenotype of gastric cancer.
Kuraoka K; Matsumura S; Hamai Y; Nakachi K; Imai K; Matsusaki K; Oue N; Ito R; Nakayama H; Yasui W
Int J Cancer; 2003 Nov; 107(4):593-6. PubMed ID: 14520697
[TBL] [Abstract][Full Text] [Related]
10. The influence of HER2 genotypes as molecular markers on breast cancer outcome.
Mutluhan H; Akbas E; Erdogan NE; Soylemez F; Senli MS; Polat A; Helvaci I; Seyrek E
DNA Cell Biol; 2008 Oct; 27(10):575-9. PubMed ID: 18721072
[TBL] [Abstract][Full Text] [Related]
11. Allelic imbalance of HER2 variant in sporadic breast and ovarian cancer.
Puputti M; Sihto H; Isola J; Butzow R; Joensuu H; Nupponen NN
Cancer Genet Cytogenet; 2006 May; 167(1):32-8. PubMed ID: 16682283
[TBL] [Abstract][Full Text] [Related]
12. Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism.
Goodman MT; McDuffie K; Kolonel LN; Terada K; Donlon TA; Wilkens LR; Guo C; Le Marchand L
Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):209-16. PubMed ID: 11303589
[TBL] [Abstract][Full Text] [Related]
13. Her2 genotype and breast cancer progression in Korean women.
An HJ; Kim NK; Oh D; Kim SH; Park MJ; Jung MY; Kang H; Kim SG; Lee KP; Lee KS
Pathol Int; 2005 Feb; 55(2):48-52. PubMed ID: 15693849
[TBL] [Abstract][Full Text] [Related]
14. Impact of RAD51 G135C and XRCC1 Arg399Gln polymorphisms on ovarian carcinoma risk in Serbian women.
Malisic EJ; Krivokuca AM; Boljevic IZ; Jankovic RN
Cancer Biomark; 2015; 15(5):685-91. PubMed ID: 26406958
[TBL] [Abstract][Full Text] [Related]
15. Allelic imbalance of HER-2 codon 655 polymorphism among different religious/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer.
Papadopoulou E; Simopoulos K; Tripsianis G; Tentes I; Anagnostopoulos K; Sivridis E; Galazios G; Kortsaris A
Neoplasma; 2007; 54(5):365-73. PubMed ID: 17918664
[TBL] [Abstract][Full Text] [Related]
16. A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer.
Nelson SE; Gould MN; Hampton JM; Trentham-Dietz A
Breast Cancer Res; 2005; 7(3):R357-64. PubMed ID: 15987431
[TBL] [Abstract][Full Text] [Related]
17. A case-control study of the HER2 Ile655Val polymorphism and risk of breast cancer in Taiwan.
Lee SC; Hou MF; Hsieh PC; Wu SH; Hou LA; Ma H; Tsai SM; Tsai LY
Clin Biochem; 2008 Feb; 41(3):121-5. PubMed ID: 18062925
[TBL] [Abstract][Full Text] [Related]
18. HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites.
Millikan R; Eaton A; Worley K; Biscocho L; Hodgson E; Huang WY; Geradts J; Iacocca M; Cowan D; Conway K; Dressler L
Breast Cancer Res Treat; 2003 Jun; 79(3):355-64. PubMed ID: 12846420
[TBL] [Abstract][Full Text] [Related]
19. Investigation of HER-2 codon 655 single nucleotide polymorphism frequency and c-ErbB-2 protein expression alterations in gastric cancer patients.
Satiroglu-Tufan NL; Bir F; Calli-Demirkan N
World J Gastroenterol; 2006 May; 12(20):3283-7. PubMed ID: 16718853
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk.
Lurie G; Wilkens LR; Thompson PJ; McDuffie KE; Carney ME; Terada KY; Goodman MT
Cancer Epidemiol Biomarkers Prev; 2007 Dec; 16(12):2566-71. PubMed ID: 18086759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
